Gilead Sciences, Inc. GILD
150.93
1.24
0.83%
as of 25 Sep
- Market cap
- $183.2B
- P/E
- 0.0×
Follow GILD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Gilead Sciences, Inc. (GILD) Return on equity
Gilead Sciences, Inc.'s return on equity over the twelve months to 30 June 2026 was −20.7%, down 61.3 percentage points from fiscal 2025 (40.7%). Over the past ten years it has ranged from 0.60% (fiscal 2020) to 103.7% (fiscal 2015); the current reading is higher than 82% of that period. That is below the Drug Manufacturers General industry median of 6.97% and above the Healthcare sector median of −32.0%.
Return on equity, annual
Annual
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 40.7% | 38.37 |
| FY2024 | 2.29% | (23.48) |
| FY2023 | 25.8% | 4.04 |
| FY2022 | 21.7% | (9.96) |
| FY2021 | 31.7% | 31.09 |
| FY2020 | 0.60% | (23.78) |
| FY2019 | 24.4% | (1.57) |
| FY2018 | 26.0% | 2.73 |
| FY2017 | 23.2% | (46.96) |
| FY2016 | 70.2% | (33.50) |
Against its own ten years
Low 0.60%
High 103.7%
Ten-year median
25.8%
Current reading's percentile
82
Return on equity against peers
| Company | Return on equity |
|---|---|
| AMGN Amgen Inc. compare | 91.5% |
| NVO Novo Nordisk A/S compare | 60.8% |
| BMY Bristol Myers Squibb Company compare | 46.6% |
| GSK GSK PLC Sponsored ADR compare | 30.7% |
| NVS Novartis AG compare | 30.4% |
| AZN AstraZeneca PLC compare | 22.0% |
| SNY Sanofi compare | 5.87% |
| PFE Pfizer Inc. compare | 4.97% |
| GILD Gilead Sciences, Inc. | −20.7% |
| Drug Manufacturers General industry median | 6.97% |
| Healthcare sector median | −32.0% |
| Market median | 1.76% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on GILD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement